Preclinical trials of a new radiopharmaceutical to treat ovarian cancer have produced successful results, dramatically limiting tumour growth and decreasing tumour mass.

Designed specifically for ovarian cancers that are resistant to traditional therapies, the new radiopharmaceutical can be produced in 25 minutes at low cost, which leads to better efficiency compared with alternative methods. This research was presented at the Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting.

According to the American Cancer Society, more than 20,000 women are diagnosed with ovarian cancer each year and nearly 14,000 will die from the disease. Ovarian cancer patients have a five-year survival rate of 49.1 percent. It is the fifth leading cause of cancer-related death among women.

In the study, researchers utilised a new generator system to develop the targeted alpha-therapy Pb-214-TCMC-trastuzumab to treat HER2-postive ovarian cancer.

Ovarian cancer cells and mice bearing ovarian cancer tumours were split into three groups: those treated with Pb-214-TCMC-trastuzumab, those treated with Pb-214-TCMC-IgG and an untreated control group. All groups were imaged over time to determine the effectiveness of the treatment.

Compared to the Pb-214-TCMC-IgG and control groups, the tumour signal for mice and cells treated with Pb-214-TCMC-trastuzumab decreased dramatically over the course of the study, signalling the efficacy of the therapy.

There were no adverse side effects from the treatment as determined by weight loss of all animals surviving.

"The short 27-minute half-life of Pb-214 is ideal for fractioned alpha particle therapeutic applications," stated Mike Zamiara, study author and president of Niowave Inc. in East Lansing, Michigan.

"The generator system can provide Pb-214 every hour, potentially providing a new source of alpha particle therapy to patients at lower cost. In the future, the generator system will be available for many therapeutic products in a turn-key system under development, providing reliable doses for improved patient care."

Source: Society of Nuclear Medicine and Molecular Imaging